Compare Pfizer Inc (PFE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs BIO-TECHNE Corp — how do they compare? Pfizer Inc trades at $28.28 (market cap $158.56B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Pfizer Inc is far larger — about 14× BIO-TECHNE Corp's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and BIO-TECHNE Corp for 64 Days on average.
| PFE | TECH | |
|---|---|---|
Market Cap | $158.56B | $11.36B |
Volume | 44,138,282 | 5,390,331 |
Sector | Health | Health |
52-Week High | $29.02 | $72.61 |
52-Week Low | $23.67 | $43.31 |
Typical Hold Time | 158 Days | 64 Days |
Enterprise Value | $210.06B | $11.39B |
Dividend Yield | 6.18% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
